ReviewJMA journal2025
The High-benefit Approach: A New Targeting Strategy in Precision Medicine.
Review in JMA journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In medicine, treatment or intervention is typically prioritized for individuals at high risk of diseases or mortality. This high-risk approach, which focuses on "high-risk" patients, has been a cornerstone of clinical decision-making. Additionally, recent advancements in precision medicine, especially those using multi-omics data to assess disease risk, have frequently been framed within this approach. However, it is not always the case that individuals at high risk of disease benefit most from the treatment of interest. In this context, we previously proposed a novel targeting strategy called the "high-benefit approach." By applying machine learning technologies to data from randomized controlled trials or observational studies, this strategy allows us to identify subpopulations likely to experience substantial benefits from the treatment and to target them, rather than those who are simply at high risk of diseases. The high-benefit approach contributes not only to effective resource allocation but also to the potential mitigation of health disparities by identifying individuals with limited or no benefits and offering alternative approaches that would be effective for them. This review paper explains the overall concept of the high-benefit approach and its potential for application in healthcare literature, particularly in advancing future precision medicine and public health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.